» Articles » PMID: 9512916

Systemic Antifungal Agents. Drug Interactions of Clinical Significance

Overview
Journal Drug Saf
Specialties Pharmacology
Toxicology
Date 1998 Mar 26
PMID 9512916
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

There are 3 main classes of systemic antifungals: the polyene macrolides (e.g. amphotericin B), the azoles (e.g. the imidazoles ketoconazole and miconazole and the triazoles itraconazole and fluconazole) and the allylamines (e.g. terbinafine). Other systemic antifungals include griseofulvin and flucytosine. Most drug-drug interactions involving systemic antifungals have negative consequences. The interactions of amphotericin B, flucytosine, griseofulvin, terbinafine and azole antifungals can be divided into the following categories: (i) additive dangerous interactions; (ii) modifications of antifungal kinetics by other drugs; and (iii) modifications of the kinetics of other drugs by antifungals. Amphotericin B and flucytosine mainly interact with other agents pharmacodynamically. Clinically important drug interactions with amphotericin B cause nephrotoxicity, hypokalaemia and blood dyscrasias. The most important drug interaction of flucytosine occurs with myelotoxic agents. Hypokalaemia can precipitate the long QT syndrome, as well as potentially lethal ventricular arrhythmias like torsade de pointes. Synergism is likely to occur when either QT interval-modifying drugs (e.g. terfenadine and astemizole) and drugs that induce hypokalaemia (e.g. amphotericin B) are coadministered. Induction and inhibition of cytochrome P450 enzymes at hepatic and extrahepatic sites are the mechanisms that underlie the most serious pharmacokinetic drug interactions of the azole antifungals. These agents have been shown to notably decrease the catabolism of numerous drugs: histamine H1 receptor antagonists, warfarin, cyclosporin, tacrolimus, digoxin, felodipine, lovastatin, midazolam, triazolam, methylprednisolone, glibenclamide (glyburide), phenytoin, rifabutin, ritonavir, saquinavir, nevirapine and nortriptyline. Non-antifungal drugs like carbamazepine, phenobarbital (phenobarbitone), phenytoin and rifampicin (rifampin) can induce the metabolism of azole antifungals. The bioavailability of ketoconazole and itraconazole is also reduced by drugs that increase gastric pH, such as H2 receptor antagonists, proton pump inhibitors, sucralfate and didanosine. Griseofulvin is an enzymatic inducer of coumarin-like drugs and estrogens, whereas terbinafine seems to have a low potential for drug interactions. Despite important advances in our understanding of the mechanisms underlying pharmacokinetic drug interactions during the 1990s, at this time they still remain difficult to predict in terms of magnitude in individual patients. This is because of the large interindividual and intraindividual variations in the catalytic activity of those metabolising enzymes that can either be induced or inhibited by various drugs. Notwithstanding these variations, increasing clinical experience is allowing pharmacokinetic interactions to be used to advantage in order to improve the tolerability of some drugs, as recently exemplified by the use of a fixed combination of ketoconazole and cyclosporin.

Citing Articles

Fragment-based development of small molecule inhibitors targeting cholesterol metabolism.

Kavanagh M, McLean K, Gilbert S, Amadi C, Snee M, Tunnicliffe R bioRxiv. 2025; .

PMID: 39803573 PMC: 11722527. DOI: 10.1101/2024.10.28.620643.


Protein kinases MpkA and SepH transduce crosstalk between CWI and SIN pathways to activate protective hyphal septation under echinocandin cell wall stress.

Doan A, Schafer J, Douglas C, Quintanilla M, Morse M, Edwards H mSphere. 2024; 10(1):e0064124.

PMID: 39670729 PMC: 11774030. DOI: 10.1128/msphere.00641-24.


Construction of warfarin population pharmacokinetics and pharmacodynamics model in Han population based on Bayesian method.

Xia X, Cai X, Chen J, Jiang S, Zhang J Sci Rep. 2024; 14(1):14846.

PMID: 38937509 PMC: 11211351. DOI: 10.1038/s41598-024-65048-7.


Association of Torsade de Pointes and QT Prolongation With Antifungal Triazoles: Analysis Using a Pharmacovigilance Database.

Ohyama K, Akiyama S, Iida M, Hori Y In Vivo. 2023; 37(6):2719-2725.

PMID: 37905641 PMC: 10621426. DOI: 10.21873/invivo.13382.


Priorities and Challenges in Methodology for Human Health Risk Assessment from Combined Exposure to Multiple Chemicals.

Nikolopoulou D, Ntzani E, Kyriakopoulou K, Anagnostopoulos C, Machera K Toxics. 2023; 11(5).

PMID: 37235216 PMC: 10224389. DOI: 10.3390/toxics11050401.


References
1.
Lown K, Kolars J, Thummel K, Barnett J, Kunze K, Wrighton S . Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos. 1994; 22(6):947-55. View

2.
Lewin M, Bryant R, Fenrich A, Grifka R . Cisapride-induced long QT interval. J Pediatr. 1996; 128(2):279-81. DOI: 10.1016/s0022-3476(96)70409-2. View

3.
Horton C, Freeman C, Nolan Jr P, Copeland 3rd J . Cyclosporine interactions with miconazole and other azole-antimycotics: a case report and review of the literature. J Heart Lung Transplant. 1992; 11(6):1127-32. View

4.
FOWLER N, McCall D, Chou T, Holmes J, HANENSON I . Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol. 1976; 37(2):223-30. DOI: 10.1016/0002-9149(76)90316-7. View

5.
Howitt K, Oziemski M . Phenytoin toxicity induced by fluconazole. Med J Aust. 1989; 151(10):603-4. DOI: 10.5694/j.1326-5377.1989.tb101301.x. View